Mexico · Delayed Price · Currency is MXN Genomma Lab Internacional Earnings Call Transcripts
Fiscal Year 2026
-
Sequential improvement in Mexico and strong LATAM growth offset ongoing U.S. weakness and market contraction. Gross margin expanded on productivity, while EBITDA margin declined due to operational deleverage. Gradual recovery and margin improvement are expected in 2026.
-
Net sales declined 4.9% year-over-year due to FX headwinds and weak Mexican consumption, but gross margin expanded and LATAM delivered strong growth. Management expects margin pressure through Q3 as investments defend market share, with recovery in Mexico anticipated later in 2026.
Fiscal Year 2025
-
2025 saw a deliberate inventory normalization in Mexico, leading to lower sales but resilient margins and strong cash flow. Productivity gains and disciplined cost management support a positive 2026 outlook, with gradual top-line recovery and EBITDA margin guidance of 23%-23.5%.
-
Sales declined due to FX and weak seasons, but EBITDA margin remained strong at 23.7% as cost efficiencies offset top-line pressure. Growth initiatives, innovation, and digital expansion are expected to drive recovery by 2026, with productivity savings reinvested to support this plan.
-
Q2 2025 saw modest sales growth, strong EBITDA margin expansion, and a 65% increase in free cash flow, despite currency headwinds and a weak beverage season in Mexico. Outlook for 2025 is cautious, but gradual growth is expected in 2026, supported by innovation, distribution expansion, and digital initiatives.
-
Q1 2025 saw 5% sales growth, 12% EBITDA growth, and 17.7% EPS increase, with strong market share gains in most categories. Strategic investments in 10 growth projects and disciplined capital allocation aim to sustain a 24% EBITDA margin and accelerate midterm sales growth.
Fiscal Year 2024
-
Q4 and full year 2024 saw robust sales and profitability growth, with net income up 97% and EPS doubling. EBITDA margin reached 23.3% for the year, and free cash flow hit a record high. Strategic reinvestment of productivity gains is set to accelerate future growth.
-
Q3 2024 saw double-digit sales and profit growth, margin expansion, and record cash flow, driven by strong execution, productivity gains, and robust performance in core markets and categories. Guidance targets 24% EBITDA margin through 2025, with continued reinvestment and disciplined capital allocation.
-
Q2 2024 saw robust sales and margin expansion, with net income up 50.1% and EBITDA margin at 22.9%. Strategic M&A, productivity gains, and strong regional performance offset FX and inflationary headwinds. Margin expansion and growth guidance remain on track.